However, the benefit in reducing stroke events was not seen in the outcome studies of SGLT-2 inhibitors (260)
"Blue Cross made these changes after careful consideration of GLP-1 weight loss drugs efficacy, safety and access, and cost," the insurer said
Remarkably, there is evidence that GLP-1 agonists can enhance left ventricular ejection fraction, inotropy, coronary blood flow, cardiac output, and vascular endothelial function because of their cardiovascular effects and decrease overall cardiovascular event risks
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
Recent regulatory guidance underscores the risks associated with compounding GLP-1s using additives such as B12 or glycine